AtriCure Newsroom

Analyst Ratings For AtriCure

BenzingaJul 8 15:02 ET

AtriCure Analyst Ratings

BenzingaJul 8 14:01 ET

Atricure's Competitive Landscape Clears: A Buy Rating Amid Delayed Threats and Growth Prospects

TipRanksJul 8 13:17 ET

Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Immunovant (IMVT) and Monte Rosa Therapeutics (GLUE)

TipRanksMay 30 07:52 ET

AtriCure Analyst Ratings

BenzingaMay 2 12:12 ET

AtriCure Analyst Ratings

BenzingaMay 2 05:44 ET

AtriCure's Strong Growth and Market Position Justify Buy Rating

TipRanksMay 2 00:50 ET

Analysts Are Bullish on These Healthcare Stocks: Atricure (ATRC), Alkermes (ALKS)

TipRanksApr 29 07:20 ET

AtriCure Analyst Ratings

BenzingaApr 23 07:41 ET

Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Sight Sciences (SGHT)

TipRanksApr 10 05:45 ET

AtriCure Analyst Ratings

BenzingaApr 10 05:34 ET

UBS Adjusts AtriCure Price Target to $58 From $57, Maintains Buy Rating

MT NewswiresFeb 16 10:55 ET

Oppenheimer Sticks to Its Hold Rating for Atricure (ATRC)

TipRanksFeb 16 07:57 ET

Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Charles River Labs (CRL) and Shockwave Medical (SWAV)

TipRanksFeb 16 07:20 ET

Atricure's Strong Performance and Growth Potential Merit a Buy Rating

TipRanksFeb 16 05:55 ET

AtriCure Analyst Ratings

BenzingaFeb 16 05:40 ET

UBS Adjusts AtriCure Price Target to $57 From $56, Maintains Buy Rating

MT NewswiresJan 22 11:38 ET

AtriCure's Growth Trajectory: A Strong Buy Rating With Revenue Surge and Strategic Expansions

TipRanksJan 9 07:47 ET

Atricure's Strong Growth and Positive Outlook Justify Buy Rating

TipRanksJan 8 13:25 ET

Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Ascendis Pharma (ASND) and G1 Therapeutics (GTHX)

TipRanksJan 8 10:10 ET